Cardiovascular Drugs and Therapy

, Volume 21, Issue 2, pp 75–76 | Cite as

Unique Effect of Nebivolol on Coronary Hemodynamics: It’s All a Matter of Flow

  • Eli I. Lev
  • Alexander Battler

The concept of coronary flow reserve (CFR) was introduced in the 1960s by Drs. JD Coffman and DE Gregg who tested the reactive hyperemia characteristics of the coronary circulation [1]. Subsequently, the innovative studies of Dr. L Gould have paved the way to better understand coronary flow physiology. Dr. Gould examined the relationship between the anatomic severity of a coronary stenosis and its flow resistance as well as reserve [2, 3]. Based on these research efforts technology has been developed to define the effect of a coronary stenosis on the distal arterial flow response. CFR measures the capacity of the two-component system of coronary artery and supplied vascular bed to achieve maximal blood flow in response to a given hyperemic stimuli. With specialized angioplasty guidewires and induction of maximal coronary blood flow, CFR is often used in research and clinical settings to determine the physiological significance of various coronary stenoses.

The effect of beta-blockers...


  1. 1.
    Coffman JD, Gregg DE. Reactive hyperemia characteristics of the myocardium. Am J Physiol 1960;199:1143–9.PubMedGoogle Scholar
  2. 2.
    Gould KL, Lipscomb K. Effects of coronary stenoses on coronary flow reserve and resistance. Am J Cardiol 1974;34:48–55.PubMedCrossRefGoogle Scholar
  3. 3.
    Gould KL, Lipscomb K, Hamilton GW. Physiologic basis for assessing critical coronary stenosis. Instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve. Am J Cardiol. 1974;33:87–94.PubMedCrossRefGoogle Scholar
  4. 4.
    Billinger M, Seiler C, Fleisch M, Eberli FR, Meier B, Hess OM. Do beta-adrenergic blocking agents increase coronary flow reserve? J Am Coll Cardiol 2001;38:1866–71.PubMedCrossRefGoogle Scholar
  5. 5.
    Togni M, Vigorito F, Windecker S, Abrecht L, Wenaweser P, Cook S, Billinger M, Meier B, Hess O. Does the β-blocker nebivolol increase coronary flow reserve? Cardiovasc Drugs Ther 2007;21.Google Scholar
  6. 6.
    Erdogan D, Gullu H, Caliskan M, Ciftci O, Topcu S, Yildirir A, Muderrisoglu H. Nebivolol improves coronary flow reserve in patients with idiopathic dilated cardiomyopathy. Heart 2007;93:319–24.PubMedCrossRefGoogle Scholar
  7. 7.
    Galderisi M, Cicala S, D’Errico A, de Divitiis O, de Simone G. Nebivolol improves coronary flow reserve in hypertensive patients without coronary heart disease. J Hypertens 2004;22:2201–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Serruys PW, di Mario C, Piek J, Schroeder E, Vrints C, Probst P, de Bruyne B, Hanet C, Fleck E, Haude M, Verna E, Voudris V, Geschwind H, Emanuelsson H, Muhlberger V, Danzi G, Peels HO, Ford AJ Jr, Boersma E. Prognostic value of intracoronary flow velocity and diameter stenosis in assessing the short- and long-term outcomes of coronary balloon angioplasty: the DEBATE study (Doppler Endpoints Balloon Angioplasty Trial Europe). Circulation 1997;96:3369–77.PubMedGoogle Scholar
  9. 9.
    Galderisi M, Cicala S, Caso P, De Simone L, D’Errico A, Petrocelli A, de Divitiis O. Coronary flow reserve and myocardial diastolic dysfunction in arterial hypertension. Am J Cardiol 2002;90:860–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Cardiology DepartmentRabin Medical CenterPetach-TikvaIsrael
  2. 2.The Sackler Faculty of MedicineTel-Aviv UniversityTel-AvivIsrael

Personalised recommendations